Physician profile
Anna A Smith
NPI 1245533520
$4,209.29
in general payments reported to CMS, 2019-2025
31 companies · $21.17 in 2025
The $21.17 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,289 · 2022: $581 · 2023: $274 · 2024: $43.73 · 2025: $21.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,529.16 | 2021 | |
| Collegium Pharmaceutical, INC. | $231.27 | 2021-2022 | |
| Abbvie INC. | $161.75 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.47 | 2021-2022 | |
| Almatica Pharma LLC | $117.08 | 2021-2022 | |
| Ibsa Pharma INC. | $101.75 | 2021-2022 | |
| Painteq LLC | $98.03 | 2021 | |
| Scilex Pharmaceuticals INC. | $73.02 | 2021-2022 | |
| Nevro Corp. | $69.96 | 2021-2022 | |
| Organon LLC | $62.36 | 2023 | Nexplanon |
| Pfizer INC. | $56.60 | 2021 | |
| Lilly USA, LLC | $53.09 | 2022 | |
| Medtronic, INC. | $50.47 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $48.65 | 2023 | |
| Allergan, INC. | $43.73 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $43.14 | 2021-2022 | |
| Grt US Holding, INC. | $42.91 | 2022 | |
| Exeltis, USA INC. | $40.53 | 2023 | Slynd |
| Relievant Medsystems, INC. | $30.40 | 2022 | |
| Arbor Pharmaceuticals, INC. | $27.28 | 2021-2022 | |
| Millicent US INC | $24.77 | 2023 | Intrarosa |
| Shield Therapeutics INC | $24.05 | 2022 | |
| Pacira Therapeutics, INC. | $22.36 | 2021 | |
| Recor Medical INC | $21.17 | 2025 | Paradise Ultrasound Renal Denervation System |
| Sumitomo Pharma America, INC. | $20.27 | 2023 | Myfembree |
| Amgen INC. | $17.43 | 2022 | |
| Biodelivery Sciences International, INC. | $16.75 | 2021 | |
| Novo Nordisk INC | $16.31 | 2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $14.07 | 2023 | Octrode |
| W. L. Gore & Associates, INC. | $13.55 | 2024 | Gore Cardioform Septal Occluder |
| Teva Pharmaceuticals USA, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.